Trellis Bioscience Raises $10M
South San Francisco-based Trellis Bioscience has raised $10M in a Series B funding, the firm said Tuesday. The round of funding came from Novartis Bioventures Ltd., which led the round. Other investors included Pac-Link Bio Venture Investment Corporation, Sagamore Bioventures LLC, Easton-Hunt Capital Partners, LP and Morgenthaler Partners VII LP. As part of the funding, Markus Goebel of Novartis Bioventures will join the firm's board. Trellis is developing antibodies for the treatment of infectious disease and oncology.
posted on Tuesday, February 13, 2007 (Link to more information)
Related companies:
Trellis Automation, Inc.
Related stories:
> Twist Bioscience Raises $33 Million More
> Twist Bioscience Buys Genome Compiler
> Crystal Bioscience Acquired By Ligand For Up To $30.5M
> Twist Bioscience Gets $37M
> Twist Bioscience Adds $27M
silicontap.com Home